In particular, patisiran, a small interfering RNA acting as a TTR silencer, approved in Italy in 2020, has been shown to stabilize the course of polyneuropathy in ATTRv, but its administration is bound to the presence of neuropathy as a manifestation [11,12]. Here, TTR is linked to polyneuropathy.